Rituximab therapy in Greek patients with rheumatoid arthritis

Aristotelis P Tsiakalos*, Nestor K Avgoustidis*, Haralampos M MoutsopoulosDepartment of Pathophysiology, Medical School, National Univercity of Athens, Athens, Greece. *These authors contributed equally to this workObjective: An open-label, prospective, uncontrolled study created to investigate clin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Haralampos M Moutsopoulos, Nestor K Avgoustidis, Aristotelis P Tsiakalos
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c6da35654e354f3ab0f1665dc902d33c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6da35654e354f3ab0f1665dc902d33c
record_format	dspace
spelling	oai:doaj.org-article:c6da35654e354f3ab0f1665dc902d33c2021-12-02T07:20:15ZRituximab therapy in Greek patients with rheumatoid arthritis1177-54751177-5491https://doaj.org/article/c6da35654e354f3ab0f1665dc902d33c2008-10-01T00:00:00Zhttp://www.dovepress.com/rituximab-therapy-in-greek-patients-with-rheumatoid-arthritis-a2514https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Aristotelis P Tsiakalos, Nestor K Avgoustidis, Haralampos M MoutsopoulosDepartment of Pathophysiology, Medical School, National Univercity of Athens, Athens, Greece. *These authors contributed equally to this workObjective: An open-label, prospective, uncontrolled study created to investigate clinical response, serological changes and side effects in Greek patients with rheumatoid arthritis (RA), after B-cell depletion with rituximab.Methods: Patients with high disease activity (disease activity score [DAS]-28 &gt; 5.1) were selected for treatment with rituximab and received two infusions, 1 gr each, 2 weeks apart. Different disease parameters (visual analog scale, DAS-28, C-reactive protein [CRP], erythrocyte sedimentation rate, health assessment questionnaire, complement (C3), C4, rheumatoid factor [RF], anti-cyclic citrullinated peptide antibody [anti-CCP], swollen joint count, tender joint count, immunoglobulin M [IgM], IgG, IgA) were performed at base line, 2, 4, and 6 months post-treatment. Response was defined according to the American College of Rheumatology (ACR) criteria.Results: Seventeen patients received therapy. Treatment led to a reduction in various disease parameters. ACR20 was achieved in 41.11% of patients by week 8, 52.94% by week 16, and 82.35% by week 24. ACR50 was achieved in 5.88% by week 8, 41.17% by week 16, and 64.7% by week 24. ACR70 was achieved only by week 24 in 23.52% of patients. Statistical analysis has shown no differences in clinical response, between RF positive/negative patients, and anti-CCP-positive/negative patients, while decline of RF was better correlated with reduction of DAS-28 than with anti-CCP.Conclusions: Rituximab is a well tolerated and effective treatment in RA. Response was not correlated to RF or anti-CCP positivity. Decline of RF was associated with clinical response and reduction of DAS-28 and CRP.Keywords: rituximab, Greek patients, rheumatoid arthritis Haralampos M MoutsopoulosNestor K AvgoustidisAristotelis P TsiakalosDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 911-916 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Haralampos M Moutsopoulos Nestor K Avgoustidis Aristotelis P Tsiakalos Rituximab therapy in Greek patients with rheumatoid arthritis
description	Aristotelis P Tsiakalos, Nestor K Avgoustidis, Haralampos M MoutsopoulosDepartment of Pathophysiology, Medical School, National Univercity of Athens, Athens, Greece. *These authors contributed equally to this workObjective: An open-label, prospective, uncontrolled study created to investigate clinical response, serological changes and side effects in Greek patients with rheumatoid arthritis (RA), after B-cell depletion with rituximab.Methods: Patients with high disease activity (disease activity score [DAS]-28 &gt; 5.1) were selected for treatment with rituximab and received two infusions, 1 gr each, 2 weeks apart. Different disease parameters (visual analog scale, DAS-28, C-reactive protein [CRP], erythrocyte sedimentation rate, health assessment questionnaire, complement (C3), C4, rheumatoid factor [RF], anti-cyclic citrullinated peptide antibody [anti-CCP], swollen joint count, tender joint count, immunoglobulin M [IgM], IgG, IgA) were performed at base line, 2, 4, and 6 months post-treatment. Response was defined according to the American College of Rheumatology (ACR) criteria.Results: Seventeen patients received therapy. Treatment led to a reduction in various disease parameters. ACR20 was achieved in 41.11% of patients by week 8, 52.94% by week 16, and 82.35% by week 24. ACR50 was achieved in 5.88% by week 8, 41.17% by week 16, and 64.7% by week 24. ACR70 was achieved only by week 24 in 23.52% of patients. Statistical analysis has shown no differences in clinical response, between RF positive/negative patients, and anti-CCP-positive/negative patients, while decline of RF was better correlated with reduction of DAS-28 than with anti-CCP.Conclusions: Rituximab is a well tolerated and effective treatment in RA. Response was not correlated to RF or anti-CCP positivity. Decline of RF was associated with clinical response and reduction of DAS-28 and CRP.Keywords: rituximab, Greek patients, rheumatoid arthritis
format	article
author	Haralampos M Moutsopoulos Nestor K Avgoustidis Aristotelis P Tsiakalos
author_facet	Haralampos M Moutsopoulos Nestor K Avgoustidis Aristotelis P Tsiakalos
author_sort	Haralampos M Moutsopoulos
title	Rituximab therapy in Greek patients with rheumatoid arthritis
title_short	Rituximab therapy in Greek patients with rheumatoid arthritis
title_full	Rituximab therapy in Greek patients with rheumatoid arthritis
title_fullStr	Rituximab therapy in Greek patients with rheumatoid arthritis
title_full_unstemmed	Rituximab therapy in Greek patients with rheumatoid arthritis
title_sort	rituximab therapy in greek patients with rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/c6da35654e354f3ab0f1665dc902d33c
work_keys_str_mv	AT haralamposmmoutsopoulos rituximabtherapyingreekpatientswithrheumatoidarthritis AT nestorkavgoustidis rituximabtherapyingreekpatientswithrheumatoidarthritis AT aristotelisptsiakalos rituximabtherapyingreekpatientswithrheumatoidarthritis
_version_	1718399479575478272

Rituximab therapy in Greek patients with rheumatoid arthritis

Ejemplares similares